B of A Securities analyst Alec Stranahan upgrades Day One Biopharmaceutical (NASDAQ:DAWN) from Underperform to Buy and raises the price target from $11 to $24.
B of A Securities Upgrades Day One Biopharmaceutical to Buy, Raises Price Target to $24
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.